There is still a lot of uncertainty about the rollout of a COVID-19 vaccine in Europe, but it now seems likely that it will be delivered to those most vulnerable to the disease by Q2 next year, which would help to reduce the risk of damaging runs on healthcare systems. This could allow governments to start to lift the majority of restrictions during the spring, and to put economic activity on a path back to normality.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to gain:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services